Trials / Recruiting
RecruitingNCT07373353
A Clinical Evaluation of AMJ-401
AMJ-401 Japan Clinical Trial
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Abbott Medical Devices · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Clinical Evaluation of AMJ-401 in the Treatment of Subjects with Ischemic Heart Disease in Japan
Detailed description
The objective of this clinical investigation is to demonstrate the safety and performance of AMJ-401 Everolimus Eluting Resorbable Scaffold System in the treatment of de novo native coronary artery lesions. Patients undergoing percutaneous coronary intervention of one or two de novo native coronary artery lesions in separate epicardial coronary vessels will be evaluated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | AMJ-401 | Patients undergoing percutaneous coronary intervention of one or two de novo native coronary artery lesions with AMJ-401 in separate epicardial coronary vessels |
Timeline
- Start date
- 2025-12-17
- Primary completion
- 2026-12-31
- Completion
- 2031-10-31
- First posted
- 2026-01-28
- Last updated
- 2026-04-07
Locations
10 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT07373353. Inclusion in this directory is not an endorsement.